About

Developing Therapies from the Protective Human Immune Response to Cancer

MabVax Therapeutics is a leading edge, clinical stage biotechnology company focused on the development of a novel pipeline of human monoclonal antibody based products discovered from the protective response of patients vaccinated against their cancer.

Identifying and Recovering the Right Antibodies

We study the protective immune response created by repeated vaccination of cancer patients. Our antibody discovery technology is able to identify and recover the antibodies patients have made against the vaccines and thus against the cancers. We search for the very best antibody any one patient makes against the vaccine and that one antibody can become our monoclonal antibody development candidate.

Integrated approach to development of companion diagnostic and therapeutic products to fully exploit our antibody discoveries

To fully exploit our lead antibody, are developing a companion diagnostic agent, a radioimmunotherapy product, and an antibody-drug conjugate product.

Our MVT-5873 Therapeutic antibody and MVT-2163 immunoPET diagnostic products are currently in Phase I trials

Phase I clinical trial for MVT-5873, as a therapeutic antibody product to treat pancreatic cancer and other CA19-9 expressing cancers was initiated in February of 2016. In July of 2016 we also initiated a phase I clinical trial for our antibody based PET imaging agent, MVT-2163, to help diagnose and manage pancreatic cancer.

View Product Pipeline

Partnerships with Leading Research Centers

A phase I clinical trial for MVT-5873, as a therapeutic antibody product to treat pancreatic cancer and other CA19-9 expressing cancers was initiated in February of 2016. In July of 2016 we also initiated a phase I clinical trial for our antibody based PET imaging agent, MVT-2163, to help diagnose and manage pancreatic cancer.

View Partnerships

Contact Us

Contact us if you have questions about our company, antibody based therapeutics or any other questions or comments.

Contact Us